ERBB2 and neoplasm: Trastuzumab, developed in 1988, is the first humanized monoclonal antibody drug for the treatment of HER2-positive breast cancer, which can selectively bind to the outer cell site of HER2 and inhibit the proliferation of tumor cells [36].